Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
Open accessAbstract
Patients with well-controlled LDL (low-density lipoprotein) levels still have residual cardiovascular risk associated with elevated triglycerides. Epidemiological studies have shown that elevated fasting triglyceride levels associate independently with incident cardiovascular events, and abundant recent human genetic data support the causality of TGRLs (triglyceride-rich lipoproteins) in atherothrombosis. Omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower blood triglyceride concentrations but likely exert additional atheroprotective properties at higher doses. Omega-3 fatty acids modulate T-cell differentiation and give rise to various prostaglandins and specialized proresolving lipid mediators that promote resolution of tissue injury and inflammation. The REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) with an EPA-only formulation lowered a composite of cardiovascular events by 25% in patients with established cardiovascular disease or diabetes mellitus and other cardiovascular risk factors. This clinical benefit likely arises from multiple molecular mechanisms discussed in this review. Indeed, human plaques readily incorporate EPA, which may render them less likely to trigger clinical events. EPA and DHA differ in their effects on membrane structure, rates of lipid oxidation, inflammatory biomarkers, and endothelial function as well as tissue distributions. Trials that have evaluated DHA-containing high-dose omega-3 fatty acids have thus far not shown the benefits of EPA alone demonstrated in REDUCE-IT. This review will consider the mechanistic evidence that helps to understand the potential mechanisms of benefit of EPA.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DHA is biochemically and pharmacologically different from EPA in membrane incorporation, lipoprotein oxidation, and generation of specialized pro-resolving lipid mediators.
“DHA is biochemically and pharmacologically different from EPA in membrane incorporation, lipoprotein oxidation, and generation of specialized pro‐resolving lipid mediators. 146 , 148”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [148]
The Comparative Biophysical and Antioxidant Properties section (page unavailable) describes different membrane conformations for EPA and DHA and says DHA’s antioxidant capacity wanes more rapidly. The EPA and DHA Give Rise to Bioactive Lipids section says omega-3 fatty acids generate specialized pro-resolving mediators, but does not establish a difference between EPA and DHA in their generation. (LLM, conf=0.84)
Experimental — accuracy not yet measuredEPA assumes an extended conformation in lipoprotein molecules and cellular membranes, allowing it to neutralize extracellular-reactive oxygen species through its conjugated double bonds mediating stabilization of unpaired electrons.
“The EPA assumes an extended conformation in lipoprotein molecules and cellular membranes, allowing it to neutralize extracellular-reactive oxygen species through its conjugated double bonds mediating stabilization of unpaired electrons [1].”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
The section on comparative biophysical and antioxidant properties says EPA adopts an extended conformation in lipoprotein particles and cellular membranes and can scavenge ROS by stabilizing unpaired electrons through its conjugated double bonds. It does not specify that the ROS scavenged by this mechanism are extracellular; the paper discusses extracellular ROS separately in connection with inflammation-resolving metabolites. Page numbers are unavailable in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measuredThe mechanisms for end point prevention appear to be attributed to the pleiotropic effects in addition to serum lipid regulation.
“The mechanisms for end point prevention appear to be attributed to the pleiotropic effects in addition to serum lipid regulation. 38 , 148”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [148]
EPA and DHA differ in their biological effects on membrane structure and lipid metabolism.
“since EPA and DHA differ in their biological effects on membrane structure and lipid metabolism”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
A significant body of evidence suggests that EPA and DHA markedly differ regarding their effects on membrane structure, inflammatory cascade, lipid oxidation, endothelial function, and tissue distribution.
“a signi fi cant body of evidence suggests that both EPA and DHA markedly differ regarding their effects on membrane structure, in fl ammatory cascade [8], lipid oxidation, endothelial function, and tissue”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
EPA and DHA have distinct biological properties not shared by each other.
“These fi ndings are plausible in the context of distinct biological properties not shared by EPA and DHA [1].”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
Besides membrane stabilization, these functions limit oxidized LDL-C levels in plasma.
“Besides membrane stabilization, these functions limit oxidized LDL-C levels in plasma.”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
Both EPA and DHA's cellular interactions vary based on their hydrocarbon length and number of double bonds.
“Both EPA and DHA ' s cellular interactions also vary based on their hydrocarbon length and number of double bonds [1].”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
DHA possesses a longer carbon chain and one additional double bond than EPA, which adds to membrane fluidity rather than stability.
“In contrast, DHA possesses a longer carbon chain and one additional double bond than does EPA, which adds to membrane fl uidity rather than stability.”
From Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021) · cites this paper as [1]
A broad literature examining effects of EPA vs EPA/DHA at molecular, cellular, imaging, and clinical endpoint levels suggests more robust benefit with purified EPA rather than mixed EPA/DHA.
“a broad literature examining effects of EPA vs EPA/DHA at the molecular and cellular levels,39, 40, 41, 42 their effects at the level of atherosclerotic plaque quantifiable with clinical imaging,8 and their effects at the clinical endpoint level evidenced in the RCT literature reviewed here, all suggest more robust benefit with purified EPA rather than mixed EPA/DHA.”
From Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality (2025) · cites this paper as [41]
Cardioprotective properties of EPA that offset inflammation and oxidative stress while improving endothelial function may have been operative in this high-risk phenotype.
“Although the study was not designed to examine mechanism(s) underlying CVD risk reduction in CKM, cardioprotective properties of EPA that offset inflammation and oxidative stress while improving endothelial function may have been operative in this high-risk phenotype [[15], [16], [17], [18]].”
From Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (2026) · cites this paper as [15]
A combination of the described molecular mechanisms is believed to contribute to the CVD protection associated with omega-3 fatty acid consumption and its added benefit on multiple other systems and pathologies.
“A combination of these mechanisms is believed to contribute to the CVD protection associated with Ω3FA consumption and the added benefit on multiple other systems and pathologies [34].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [34]
These properties provide a mechanistic explanation for how omega-3 PUFAs may protect the heart.
“These properties offer a mechanistic framework by which omega-3 PUFAs exert cardioprotective effects”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [23]
Omega-3 PUFAs have electrophysiological, vascular, and antioxidative effects.
“have electrophysiological, vascular, and antioxidative effects”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [23]
Omega-3 PUFAs change the structure and function of cellular phospholipid membranes.
“Omega-3 PUFAs alter the structure and function of cellular phospholipid membranes”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [23]
The reason for the difference between REDUCE-IT and STRENGTH remains unclear, and triglyceride-independent effects of EPA may partly explain the cardiovascular benefits in REDUCE-IT.
“It remains unclear as to why these differences exist and brings to the fore the hypothesis that triglycerideindependent effects of EPA may be in part responsible for the CV benefits seen in the REDUCE-IT trial”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [23]
EPA has additional effects on lipoproteins and atherosclerotic plaque that may contribute to its antiatherogenic properties.
“EPA exerts additional effects on lipoproteins and atherosclerotic plaque, which may contribute to its antiatherogenic properties”
From Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids (2021) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · see citing works
Self-citationEndothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9265 · Cited by 5,074 · see citing works
Prediction of Cardiovascular Events and All-Cause Mortality With Arterial Stiffness
Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.061 · Cited by 4,165 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · see citing works
Self-citationEfficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159 · see citing works
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552 · see citing works
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · see citing works
Oh, D. Y., Talukdar, S., Bae, E. J., Imamura, T., Morinaga, H., Fan, W., Li, P., Lu, W. J., Watkins, S. M., & Olefsky, J. M. (2010) · Cell · doi:10.1016/j.cell.2010.07.041 · Cited by 2,428 · see citing works
Role of endothelium-derived nitric oxide in the regulation of blood pressure.
Rees, D. D., Palmer, R. M. J., & Moncada, S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3375 · Cited by 1,827 · see citing works
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works
The oxidation hypothesis of atherosclerosis
Witztum, J. L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92346-9 · Cited by 1,394 · see citing works
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262 · see citing works
Self-citationDistribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162 · see citing works
Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H. A., Johnson, L., Franco, O. H., Butterworth, A. S., Forouhi, N. G., Thompson, S. G., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1788 · Cited by 1,139 · see citing works
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · see citing works
Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms
Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.6.935 · Cited by 950 · see citing works
Dietary (n-3) Fatty Acids and Brain Development1
Innis, S. M. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.4.855 · Cited by 906 · see citing works
Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 780 · see citing works
Kojda, G. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00169-8 · Cited by 769 · see citing works
Lewis A. Conner Memorial Lecture
Steinberg, D. H. (1997) · Circulation · doi:10.1161/01.cir.95.4.1062 · Cited by 743 · see citing works
The oxidative modification hypothesis of atherogenesis: an overview
Chisolm, G. M., & Steinberg, D. H. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00344-0 · Cited by 742 · see citing works
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698 · see citing works
Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2017.5205 · Cited by 632 · see citing works
Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., Vollenweider, P., Pedrazzini, T., Nicod, P., Thorens, B., et al. (2001) · Circulation · doi:10.1161/01.cir.104.3.342 · Cited by 533 · see citing works
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490 · see citing works
Caterina, R. D., Cybulsky, M. I., Clinton, S. K., Gimbrone, M. A., & Libby, P. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.11.1829 · Cited by 470 · see citing works
Self-citationNutrition in Brain Development and Aging: Role of Essential Fatty Acids
Uauy, R. D., & Dangour, A. D. (2006) · Nutrition Reviews · doi:10.1301/nr.2006.may.s24-s33 · Cited by 417 · see citing works
Mori, T. A., Bao, D. Q., Burke, V., Puddey, I. B., & Beilin, L. J. (1999) · Hypertension · doi:10.1161/01.hyp.34.2.253 · Cited by 407 · see citing works
Del Gobbo, L. C., Imamura, F., Aslibekyan, S., Marklund, M., Virtanen, J. K., Wennberg, M., Yakoob, M. Y., Chiuve, S. E., dela Cruz, L., Frazier-Wood, A. C., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2925 · Cited by 404 · see citing works
Terano, T., Hirai, A., Hamazaki, T., Kobayashi, S., Fujita, T., Tamura, Y., & Kumagai, A. (1983) · Atherosclerosis · doi:10.1016/0021-9150(83)90181-8 · Cited by 390 · see citing works
(n-3) Fatty Acids and Cardiovascular Health: Are Effects of EPA and DHA Shared or Complementary?
Mozaffarian, D., & Wu, J. H. Y. (2012) · The Journal of Nutrition · doi:10.3945/jn.111.149633 · Cited by 368 · see citing works
Bays, H. E., Ballantyne, C. M., Kastelein, J. J., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.04.015 · Cited by 358 · see citing works
Chiurchiù, V., Leuti, A., Dalli, J., Jacobsson, A., Battistini, L., Maccarrone, M., & Serhan, C. N. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7483 · Cited by 356 · see citing works
Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Stein, E., Isaacsohn, J. L., Braeckman, R. A., & Soni, P. N. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.05.031 · Cited by 342 · see citing works
Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality
Marklund, M., Wu, J. H. Y., Imamura, F., Gobbo, L. C. D., Fretts, A. M., de Goede, J., Shi, P., Tintle, N., Wennberg, M., Aslibekyan, S. W., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038908 · Cited by 340 · see citing works
Pradhan, A. D., Paynter, N. P., Everett, B. M., Glynn, R. J., Amarenco, P., Elam, M., Ginsberg, H., Hiatt, W. R., Ishibashi, S., Koenig, W., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.011 · Cited by 319 · see citing works
Self-citationHolvoet, P., Kritchevsky, S. B., Tracy, R. P., Mertens, A. C., Rubin, S. M., Butler, J., Goodpaster, B. H., & Harris, T. B. (2004) · Diabetes · doi:10.2337/diabetes.53.4.1068 · Cited by 318 · see citing works
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316 · see citing works
Role of NLRP3 Inflammasomes in Atherosclerosis
Karasawa, T., & Takahashi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17001 · Cited by 277 · see citing works
Adaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 269 · see citing works
Effects of Icosapent Ethyl on Total Ischemic Events
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.032 · Cited by 259 · see citing works
Self-citationAllaire, J., Couture, P., Leclerc, M., Charest, A., Marin, J., Lépine, M.-C., Talbot, D., Tchernof, A., & Lamarche, B. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.131896 · Cited by 252 · see citing works
Cawood, A. L., Ding, R., Napper, F. L., Young, R. H., Williams, J. A., Ward, M. J., Gudmundsen, O., Vige, R., Payne, S. P. K., Ye, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.022 · Cited by 245 · see citing works
Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
Mitchell, J. A., & Kirkby, N. S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14167 · Cited by 217 · see citing works
Docosahexaenoic acid domains: the ultimate non-raft membrane domain
Wassall, S. R., & Stillwell, W. H. (2008) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2008.02.010 · Cited by 208 · see citing works
Walter, M. F., Jacob, R. F., Jeffers, B., Ghadanfar, M. M., Preston, G. M., Buch, J., & Mason, R. P. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.08.029 · Cited by 205 · see citing works
Self-citationEffects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans
Grimsgaard, S., Bønaa, K. H., Hansen, J., & Myhre, E. S. P. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.1.52 · Cited by 201 · see citing works
Woodman, R. J., Mori, T. A., Burke, V., Puddey, I. B., Barden, A. E., Watts, G. F., & Beilin, L. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00307-6 · Cited by 198 · see citing works
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195 · see citing works
Self-citationCholesterol Crystals and Inflammation
Grebe, A., & Latz, E. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-012-0313-z · Cited by 192 · see citing works
Weber, C., Erl, W., Pietsch, A., Danesch, U., & Weber, P. C. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.5.622 · Cited by 188 · see citing works
Bhatt, D. L., Steg, P. G., Brinton, E. A., Jacobson, T. A., Miller, M., Tardif, J., Ketchum, S. B., Doyle, R. T., Murphy, S. A., Soni, P. N., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22692 · Cited by 183 · see citing works
Self-citationShaikh, S. R., Kinnun, J. J., Leng, X., Williams, J. A., & Wassall, S. R. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.04.020 · Cited by 179 · see citing works
Mason, R. P., Jacob, R. F., Shrivastava, S., Sherratt, S. C. R., & Chattopadhyay, A. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.10.002 · Cited by 179 · see citing works
Self-citationWatanabe, T., Ando, K., Daidoji, H., Otaki, Y., Sugawara, S., Matsui, M., Ikeno, E., Hirono, O., Miyawaki, H., Yashiro, Y., et al. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.07.007 · Cited by 177 · see citing works
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175 · see citing works
Boosting Inflammation Resolution in Atherosclerosis
Fredman, G., & Tabas, I. A. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.018 · Cited by 173 · see citing works
Tulenko, T. N., Chen, M., Mason, P. E., & Mason, R. P. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33861-x · Cited by 172 · see citing works
Self-citationDocosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains
Williams, J. A., Batten, S. E., Harris, M., Rockett, B. D., Shaikh, S. R., Stillwell, W., & Wassall, S. R. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.06.016 · Cited by 168 · see citing works
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167 · see citing works
Mita, T., Watada, H., Ogihara, T., Nomiyama, T., Ogawa, O., Kinoshita, J., Shimizu, T., Hirose, T., Tanaka, Y., & Kawamori, R. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.005 · Cited by 145 · see citing works
Bays, H. E., Ballantyne, C. M., Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-012-0002-3 · Cited by 141 · see citing works
Satoh, N., Shimatsu, A., Kotani, K., Sakane, N., Yamada, K., Suganami, T., Kuzuya, H., & Ogawa, Y. (2006) · Diabetes Care · doi:10.2337/dc06-1179 · Cited by 137 · see citing works
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136 · see citing works
Self-citationShaikh, S. R. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.07.001 · Cited by 134 · see citing works
Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.025 · Cited by 133 · see citing works
Preston Mason, R. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0762-1 · Cited by 129 · see citing works
Cicero, A. F. G., Ertek, S., & Borghi, C. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109788340659 · Cited by 120 · see citing works
Omega-3 fatty acids, lipid rafts, and T cell signaling
Hou, T. Y., McMurray, D. N., & Chapkin, R. S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.091 · Cited by 113 · see citing works
Lawler, P. R., Kotrri, G., Koh, M., Goodman, S. G., Farkouh, M. E., Lee, D. S., Austin, P. C., Udell, J. A., & Ko, D. T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz767 · Cited by 113 · see citing works
Yamada, H., Yoshida, M., Nakano, Y., Suganami, T., Satoh, N., Mita, T., Azuma, K., Itoh, M., Yamamoto, Y., Kamei, Y., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.171736 · Cited by 112 · see citing works
Mason, R. P., & Sherratt, S. C. R. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.127 · Cited by 108 · see citing works
Self-citationZhang, P., Smith, R., Chapkin, R. S., & McMurray, D. N. (2005) · Journal of Nutrition · doi:10.1093/jn/135.7.1745 · Cited by 105 · see citing works
Nomura, S., Inami, N., Shouzu, A., Omoto, S., Kimura, Y., Takahashi, N., Tanaka, A., Urase, F., Maeda, Y., Ohtani, H., et al. (2009) · Platelets · doi:10.1080/09537100802409921 · Cited by 98 · see citing works
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Jiao, L., Tardif, J.-C., Gregson, J., Pocock, S. J., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.043 · Cited by 97 · see citing works
Self-citationMonk, J. M., Hou, T. Y., Turk, H. F., Weeks, B. R., Wu, C., McMurray, D. N., & Chapkin, R. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049739 · Cited by 95 · see citing works
Alfaddagh, A., Elajami, T. K., Ashfaque, H., Saleh, M. A., Bistrian, B. R., & Welty, F. K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006981 · Cited by 95 · see citing works
Sherratt, S. C. R., & Mason, R. P. (2018) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2018.01.002 · Cited by 95 · see citing works
Self-citationBays, H. E., Braeckman, R. A., Ballantyne, C. M., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.07.001 · Cited by 94 · see citing works
Tanaka, N. K., Ishida, T., Nagao, M., Mori, T., Monguchi, T., Sasaki, M., Mori, K., Kondo, K., Nakajima, H., Honjo, T., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.011 · Cited by 92 · see citing works
Docosahexaenoic Acid Enhances Segregation of Lipids between Raft and Nonraft Domains: 2H-NMR Study
Soni, S. P., LoCascio, D. S., Liu, Y., Williams, J. A., Bittman, R., Stillwell, W., & Wassall, S. R. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.123612 · Cited by 89 · see citing works
Nosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.105 · Cited by 88 · see citing works
Nomura, S., Kanazawa, S., & Fukuhara, S. (2003) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00172-1 · Cited by 86 · see citing works
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513000200 · Cited by 86 · see citing works
Self-citationTriglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85 · see citing works
Self-citationMason, R. P., Dawoud, H., Jacob, R. F., Sherratt, S. C. R., & Maliñski, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.118 · Cited by 84 · see citing works
Self-citationIntercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis
Onat, U. İ., Yıldırım, A., Tufanlı, Ö., Çimen, İ., Kocatürk, B., Veli, Z., Hamid, S. M., Shimada, K., Chen, S., Sin, J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.055 · Cited by 84 · see citing works
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz778 · Cited by 81 · see citing works
Self-citationMason, R. P., & Jacob, R. F. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.016 · Cited by 78 · see citing works
Self-citationBudoff, M. J., Muhlestein, J. B., Le, V. T., May, H. T., Roy, S. K., & Nelson, J. R. (2018) · Clinical Cardiology · doi:10.1002/clc.22856 · Cited by 73 · see citing works
Mason, R. P., Sherratt, S. C. R., & Jacob, R. F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000379 · Cited by 72 · see citing works
Self-citationEPA, but not DHA, decreases mean platelet volume in normal subjects
Park, Y., & Harris, W. S. (2002) · Lipids · doi:10.1007/s11745-006-0984-1 · Cited by 71 · see citing works
Satoh‐Asahara, N., Shimatsu, A., Sasaki, Y., Nakaoka, H., Himeno, A., Tochiya, M., Kono, S., Takaya, T., Ono, K., Wada, H., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0269 · Cited by 64 · see citing works
Walter, M. F., Jacob, R. F., Bjork, R. E., Jeffers, B., Buch, J., Mizuno, Y., & Mason, R. P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.051 · Cited by 63 · see citing works
Self-citationDavidson, M. H., Rosenson, R. S., Maki, K. C., Nicholls, S. J., Ballantyne, C. M., Mazzone, T., Carlson, D. M., Williams, L. A., Kelly, M. T., Camp, H. S., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302926 · Cited by 63 · see citing works
n3 PUFAs Reduce Mouse CD4+ T-Cell Ex Vivo Polarization into Th17 Cells
Monk, J. M., Hou, T. Y., Turk, H. F., McMurray, D. N., & Chapkin, R. S. (2013) · Journal of Nutrition · doi:10.3945/jn.113.178178 · Cited by 61 · see citing works
Yamada, H., Umemoto, T., Kakei, M., Momomura, S., Kawakami, M., Ishikawa, S., & Hara, K. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0188-0 · Cited by 60 · see citing works
Braeckman, R. A., Stirtan, W. G., & Soni, P. N. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.84 · Cited by 58 · see citing works
Braeckman, R. A., Manku, M. S., Bays, H. E., Stirtan, W. G., & Soni, P. N. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.07.005 · Cited by 54 · see citing works
Eicosapentaenoic Acid-Enriched High-Density Lipoproteins Exhibit Anti-Atherogenic Properties
Tanaka, N. K., Irino, Y., Shinohara, M., Tsuda, S., Mori, T., Nagao, M., Oshita, T., Mori, K., Hara, T., Toh, R., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-17-0294 · Cited by 54 · see citing works
Alfaddagh, A., Elajami, T. K., Saleh, M. A., Mohebali, D., Bistrian, B. R., & Welty, F. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.04.213 · Cited by 53 · see citing works
Dunbar, R. L., Nicholls, S. J., Maki, K. C., Roth, E. M., Orloff, D. G., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0100-8 · Cited by 52 · see citing works
Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.005 · Cited by 52 · see citing works
Sherratt, S. C. R., & Mason, R. P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.062 · Cited by 51 · see citing works
Self-citationBiomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.
Marklund, M., Wu, J. H. Y., Imamura, F., et al. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.36839 · Cited by 51 · see citing works
Clubb, F. J., Schmitz, J. M., Butler, M. M., et al. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.4.529 · Cited by 49 · see citing works
Lefils-Lacourtablaise, J., Socorro, M., Géloën, A., Daira, P., Debard, C., Loizon, E., Guichardant, M., Domínguez, Z., Vidal, H., Lagarde, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063997 · Cited by 49 · see citing works
Docosahexaenoyl Chains Isomerize on the Sub-Nanosecond Time Scale
Soubias, O., & Gawrisch, K. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068856c · Cited by 48 · see citing works
Ito, R., Satoh‐Asahara, N., Yamakage, H., Sasaki, Y., Odori, S., Kono, S., Wada, H., Suganami, T., Ogawa, Y., Hasegawa, K., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.19976 · Cited by 47 · see citing works
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47 · see citing works
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46 · see citing works
Takaki, A., Umemoto, S., Ono, K., Seki, K., Ryoke, T., Fujii, A., Itagaki, T., Harada, M., Tanaka, M., 米澤, 孝., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.7260 · Cited by 41 · see citing works
Sato, T., Horikawa, M., Takei, S., Yamazaki, F., Ito, T. K., Kondo, T., Sakurai, T., Kahyo, T., Ikegami, K., Sato, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313093 · Cited by 41 · see citing works
Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease
Picard, F., Bhatt, D. L., Ducrocq, G., Elbez, Y., Ferrari, R., Ford, I., Tardif, J.-C., Tendera, M., Fox, K. M., & Steg, P. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.016 · Cited by 39 · see citing works
Self-citationGlucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation
Self-Medlin, Y., Byun, J., Jacob, R. F., Mizuno, Y., & Mason, R. P. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.04.004 · Cited by 37 · see citing works
Self-citationBhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz179 · Cited by 37 · see citing works
Self-citationCardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33 · see citing works
Self-citationSasaki, J., Miwa, T., & Odawara, M. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej11-0394 · Cited by 31 · see citing works
Wang, Y., He, J., & Yang, J. (2018) · Medical Science Monitor · doi:10.12659/msm.909098 · Cited by 30 · see citing works
N-3 Polyunsaturated Fatty Acids, Lipid Microclusters, and Vitamin E
Shaikh, S. R., Wassall, S. R., Brown, D. A., & Kosaraju, R. (2015) · Current topics in membranes · doi:10.1016/bs.ctm.2015.03.003 · Cited by 26 · see citing works
Cardiovascular Risk Reduction with Icosapent Ethyl
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902165 · Cited by 24 · see citing works
Targeting RNA to lower triglycerides: long strides from short molecules
Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14 · see citing works
Self-citationBhatt, D. L., Steg, P. G., Miller, M., Juliano, R. A., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.007 · Cited by 11 · see citing works
Self-citationEffect of eicosapentaenoic acid on regional arterial stiffness: Assessment by tissue Doppler imaging
Haiden, M. (2012) · World Journal of Cardiology · doi:10.4330/wjc.v4.i8.256 · Cited by 10 · see citing works
Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?
Fruchart, J., Santos, R. D., Yamashita, S., Libby, P., Fruchart, J., Santos, R. D., Yamashita, S., Aikawa, M., Libby, P., Plutzky, J., et al. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.034 · Cited by 6 · see citing works
Self-citationBallantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J. P., Otvos, J. D., Stirtan, W. G., & Soni, P. N. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.071 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [3]Bhatt DL. Residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT! Eur Heart J. 2019; 40: 1174– 1175.30982067
Cited by
Sorted by citations
The changing landscape of atherosclerosis
Libby, P. (2021) · Nature · doi:10.1038/s41586-021-03392-8 · Cited by 2,873 · see citing works
Self-citationInflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473 · see citing works
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
Khan, S. U., Lone, A. N., Khan, M. S., Virani, S. S., Blumenthal, R. S., Nasir, K., Miller, M., Michos, E. D., Ballantyne, C. M., Boden, W. E., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100997 · Cited by 411 · see citing works
“In vivo, omega-3 FAs (EPA and DHA) as well as omega-6 FA (arachidonic acid [AA]) are involved in formation of key regulators of inflammation, vasodilation, and platelet aggregation [26,27].”
BackgroundInfluentialSelf-citationVirani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341 · see citing works
Saini, R. K., Prasad, P., Sreedhar, R. V., Akhilender Naidu, K., Shang, X., & Keum, Y.-S. (2021) · Antioxidants · doi:10.3390/antiox10101627 · Cited by 337 · see citing works
The Potential and Challenge of Microalgae as Promising Future Food Sources
Chen, C., Tang, T., Shi, Q., Zhou, Z., & Fan, J. (2022) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2022.06.016 · Cited by 229 · see citing works
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171 · see citing works
Self-citationJeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132 · see citing works
Ridker, P. M., Rifai, N., MacFadyen, J., Glynn, R. J., Jiao, L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Tardif, J.-C., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059410 · Cited by 131 · see citing works
Self-citationEstablished and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109 · see citing works
“Albeit the exact MoA is unknown, scientists hypothesize that EPA exerts pleiotropic cardiovascular effects beyond lowering triglycerides: antiinflammatory, anti-thrombotic, membrane stabilizing, plaque stabilizing, anti-arrhythmic and anti-hypertensive [105, 106, 108, 109].”
BackgroundMineral oil: safety and use as placebo in REDUCE-IT and other clinical studies
Olshansky, B., Chung, M. K., Budoff, M. J., Philip, S., Jiao, L., Doyle, Jr., Copland, C., Giaquinto, A., Juliano, R. A., & Bhatt, D. L. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa117 · Cited by 103 · see citing works
Self-citationMiyauchi, K., Iwata, H., Nishizaki, Y., Inoue, T., Hirayama, A., Kimura, K., Ozaki, Y., Murohara, T., Ueshima, K., Kuwabara, Y., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065520 · Cited by 92 · see citing works
Wang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., Chen, B. E., & Li, X. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029512 · Cited by 73 · see citing works
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63 · see citing works
Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61 · see citing works
Self-citationZelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017401 · Cited by 26 · see citing works
“28 In the current study, although the individual subtypes of long-chain ω 3-PUFAs showed a directionally concordant relationship with sudden cardiac death, the relationship appeared to be more attenuated for ALA.”
Cardiovascular Risk Reduction with Icosapent Ethyl
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902165 · Cited by 24 · see citing works
Dinu, M., Sofi, F., Lotti, S., Colombini, B., Mattioli, A. V., Catapano, A. L., Casula, M., Baragetti, A., Wong, N. D., Steg, P. G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae184 · Cited by 17 · see citing works
Maki, K. C., Bays, H. E., Ballantyne, C. M., Underberg, J. A., Kastelein, J. J. P., Johnson, J. B., Ferguson, J. J., Bays, H., Blomer, A., Kelley, K., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024176 · Cited by 12 · see citing works
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead114 · Cited by 11 · see citing works
Self-citationVirani, S. S., Nambi, V., & Ballantyne, C. M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab010 · Cited by 10 · see citing works
Lachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s377935 · Cited by 7 · see citing works
Sheppard, J. P., Palatnic, L., Lakshmanan, S., Drago, T., Bhogal, J., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.102149 · Cited by 3 · see citing works
Self-citationIcosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101387
“Although the study was not designed to examine mechanism (s) underlying CVD risk reduction in CKM, cardioprotective properties of EPA that offset inflammation and oxidative stress while improving endothelial function may have been operative in this high-risk phenotype [15 – 18].”
Self-citation
- Authors
- Mason, R. P., Libby, P., & Bhatt, D. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Mason, R. Preston
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2020-05
- Volume
- 40
- Issue
- 5
- Pages
- 1135-1147
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC7176343
- OpenAlex
- W3013214255
- Cited by
- 407
- References
- 128
- Citations by year
- 2026: 43 · 2025: 56 · 2024: 61 · 2023: 68 · 2022: 69 · 2021: 67 · 2020: 38 · 2019: 2 · 2015: 2
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Brigham and Women's Hospital
- Cleveland Clinic
- CSL Behring
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Ironwood Pharmaceuticals, Incorporated
- Ionis Pharmaceuticals
- Amarin Corporation
- Medicines Company
- IFM Therapeutics
- Kowa Company
- XBiotech
- Eisai
- Novo Nordisk
- Idorsia Pharmaceuticals
- Esperion Therapeutics
- St. Jude Medical
- National Heart, Lung, and Blood Institute (R01HL080472, R01HL134892)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- eicosapentaenoic acid, omega-3 fatty acids, cardioprotection, triglyceride-rich lipoproteins, residual cardiovascular risk, atherothrombosis, REDUCE-IT trial, plaque composition, T cell differentiation, specialized pro-resolving mediators, prostaglandins, docosahexaenoic acid, endothelial function, inflammation, lipid oxidation, LDL cholesterol
- MeSH terms
- Animals, Anti-Inflammatory Agents, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Inflammation, Lipids, Risk Factors, Eicosapentaenoic Acid, Biomarkers, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Dietary Supplements, Dyslipidemias, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
